Haemonetics Corporation (HAE) Shares Bought by Strs Ohio

Strs Ohio increased its stake in shares of Haemonetics Corporation (NYSE:HAE) by 1.0% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 29,300 shares of the medical instruments supplier’s stock after buying an additional 300 shares during the period. Strs Ohio owned approximately 0.06% of Haemonetics Corporation worth $1,157,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its position in Haemonetics Corporation by 5.0% in the first quarter. Bank of New York Mellon Corp now owns 756,590 shares of the medical instruments supplier’s stock valued at $30,697,000 after buying an additional 35,852 shares in the last quarter. US Bancorp DE boosted its position in Haemonetics Corporation by 4.3% in the first quarter. US Bancorp DE now owns 22,013 shares of the medical instruments supplier’s stock valued at $893,000 after buying an additional 917 shares in the last quarter. AMG National Trust Bank boosted its position in Haemonetics Corporation by 12.1% in the first quarter. AMG National Trust Bank now owns 17,429 shares of the medical instruments supplier’s stock valued at $707,000 after buying an additional 1,883 shares in the last quarter. American Century Companies Inc. boosted its position in Haemonetics Corporation by 0.9% in the first quarter. American Century Companies Inc. now owns 45,846 shares of the medical instruments supplier’s stock valued at $1,860,000 after buying an additional 405 shares in the last quarter. Finally, Great West Life Assurance Co. Can boosted its position in Haemonetics Corporation by 7.2% in the first quarter. Great West Life Assurance Co. Can now owns 73,789 shares of the medical instruments supplier’s stock valued at $2,993,000 after buying an additional 4,986 shares in the last quarter.

Shares of Haemonetics Corporation (NYSE HAE) opened at 42.50 on Monday. The company has a 50-day moving average of $40.24 and a 200 day moving average of $40.17. Haemonetics Corporation has a 12-month low of $32.76 and a 12-month high of $43.74. The stock has a market capitalization of $2.24 billion, a price-to-earnings ratio of 551.95 and a beta of 0.90.

Haemonetics Corporation (NYSE:HAE) last announced its quarterly earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.02. The company had revenue of $211 million during the quarter, compared to analysts’ expectations of $211.29 million. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. Haemonetics Corporation’s quarterly revenue was up .5% on a year-over-year basis. During the same period last year, the business earned $0.25 earnings per share. Analysts predict that Haemonetics Corporation will post $1.61 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Haemonetics Corporation (HAE) Shares Bought by Strs Ohio” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://sportsperspectives.com/2017/08/14/haemonetics-corporation-hae-shares-bought-by-strs-ohio.html.

Several equities analysts have issued reports on the stock. Zacks Investment Research cut shares of Haemonetics Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. Jefferies Group LLC restated a “buy” rating and set a $42.00 target price on shares of Haemonetics Corporation in a research note on Monday, May 8th. TheStreet upgraded shares of Haemonetics Corporation from a “c” rating to a “b-” rating in a research note on Monday, August 7th. BidaskClub upgraded shares of Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 8th. Finally, Barrington Research raised shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price target for the company in a research report on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $40.63.

In related news, Director Ronald Merriman sold 17,471 shares of Haemonetics Corporation stock in a transaction that occurred on Monday, May 22nd. The stock was sold at an average price of $40.33, for a total transaction of $704,605.43. Following the completion of the transaction, the director now directly owns 24,925 shares in the company, valued at $1,005,225.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is currently owned by company insiders.

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply